Home  |  Contact

Cellosaurus ZR75B Ad120 (CVCL_ZZ26)

[Text version]
Cell line name ZR75B Ad120
Accession CVCL_ZZ26
Resource Identification Initiative To cite this cell line use: ZR75B Ad120 (RRID:CVCL_ZZ26)
Comments Population: Caucasian.
Doubling time: 47.8 hours (PubMed=8562478; PubMed=9815641).
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
  • Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_5614 (ZR-75-B)
Sex of cell Female
Age at sampling 63Y
Category Cancer cell line
Publications

PubMed=8562478
Wosikowski K., Regis J.T., Robey R.W., Alvarez M., Buters J.T.M., Gudas J.M., Bates S.E.
Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Cell Growth Differ. 6:1395-1403(1995)

PubMed=9815641
Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E.
Altered gene expression in drug-resistant human breast cancer cells.
Clin. Cancer Res. 3:2405-2414(1997)

Cross-references
Cell line databases/resources cancercelllines; CVCL_ZZ26
Encyclopedic resources Wikidata; Q102115155
Entry history
Entry creation29-Oct-2020
Last entry update05-Oct-2023
Version number7